Journal of Neurogastroenterology and Motility : eISSN 2093-0887 / pISSN 2093-0879

Table. 3.

Study Characteristics of Studies Evaluating Symptomatic Response for Antibiotics in Irritable Bowel Syndrome Patients With Small Intestinal Bacterial Overgrowth Compared to No Small Intestinal Bacterial Overgrowth

Study Analyzed study type Country Sample size (% female) IBS type Method to diagnose SIBO Criteria for symptomatic improvement Antibiotic used Duration of therapy (day) Duration of follow-up (day) Rate of improvement for patients with SIBO Rate of improvement for patients without SIBO
Pimentel et al,22 2003 Cohort US 55 (62%)

Rome I

IBS-D: 48% IBS-C: 35%

Other: 13%

Lactulose breath test ≥ 50% reduction in composite score of abdominal pain, diarrhea, and constipation Neomycin 500 mg BID 10 7 21/46 (45.7%) 3/9 (33.3%)
Ghoshal et al,23 2016 Cohort India 40 (19%) Rome III IBS Duodenal aspirate 103 CFU No longer meeting Rome III criteria for IBS Norfloxacin 400 mg BID 10 30 12/19 (63.2%) 3/21 (14.3%)
Rezaie et al,21 2019 Cohort US 93 (67%) Rome III IBS-D Lactulose breath test ≥ 30% decrease weekly abdominal pain and ≥ 50% decrease in day/wk with BSS type 6 or 7 stool during ≥ 2 wk Rifaximin 550 mg TID 14 28 37/62 (59.6%) 8/31 (43.9%)
Zhuang et al,20 2020 Cohort China 78 (33%) Rome IV IBS-D Lactulose breath test 50% improvement in the global GI symptoms Rifaximin 400 mg TID 14 14 18/45 (40.0%) 8/33 (24.2%)

IBS, irritable bowel syndrome; SIBO, small intestinal bacterial overgrowth; US, United States; IBS-D, diarrhea predominant IBS; IBS-C, constipation predominant IBS; BID, twice a day; CFU, colony forming unit; BSS, Bristol stool scale; TID, three times a day; GI, gastrointestinal.

J Neurogastroenterol Motil 2024;30:7~16 https://doi.org/10.5056/jnm22187
© J Neurogastroenterol Motil